Blog
RSS FeedPosted by Michael Wonder on 29 Aug 2018
Cancer charities dismayed after ‘new generation’ therapy rejected as too expensive
29 August 2018 - A NICE committee said the cost of the drug was “too high for it to be considered ...
Posted by Michael Wonder on 28 Aug 2018
Cabometyx gets NICE recommendation in renal cell carcinoma
24 August 2018 - French drugmaker Ipsen that it has received a recommendation from NICE for National Health Service funding ...
Posted by Michael Wonder on 23 Aug 2018
NICE publishes preliminary guidance on new combo product for AML
23 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using liposomal cytarabine ...
Posted by Michael Wonder on 23 Aug 2018
NICE publishes final guidance for dinutuximab
22 August 2018 - Dinutuximab is used to treat children with brain cancer. ...
Posted by Michael Wonder on 17 Aug 2018
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
17 August 2018 - NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used ...
Posted by Michael Wonder on 15 Aug 2018
‘I wish they approved this new leukaemia drug two years ago, then I wouldn’t have had to go through hell’
12 August 2018 - Chloe Pinder was just 23 when she was diagnosed with acute lymphoblastic leukaemia, a very rare type ...
Posted by Michael Wonder on 09 Aug 2018
NICE changes its mind on Pfizer’s Besponsa
9 August 2018 - NICE has reversed its draft decision rejecting Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults ...
Posted by Michael Wonder on 08 Aug 2018
Lenvatinib mesylate and sorafenib tosylate for the treatment of patients with differentiated thyroid cancer after the use of radioactive iodine
8 August 2018 - NICE has published evidence-based recommendations on the use of lenvatinib mesylate (Lenvima) and sorafenib tosylate (Nexavar) ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes draft guidance on new use for lenvatinib mesylate
8 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using lenvatinib mesylate ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes final appraisal determination for Alecensa
8 August 2018 - The determination relates to the use of alectinib hydrochloride for the first-line treatment of patients with untreated ...
Posted by Michael Wonder on 26 Jul 2018
NICE backing for Keytruda in classical Hodgkin's lymphoma
26 July 2018 - NICE has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund ...
Posted by Michael Wonder on 12 Jul 2018
NICE says no to Darzalex
12 July 2018 - NICE says no to myeloma ‘game changer’. ...
Posted by Michael Wonder on 12 Jul 2018
Cancer drug for children recommended after becoming cost effective for NHS patients
12 July 2018 - Around 60% of children with high-risk neuroblastoma could be treated with dinutuximab beta. ...
Posted by Michael Wonder on 11 Jul 2018
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology
11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...
Posted by Michael Wonder on 04 Jul 2018
Two of three US pharma companies receive Independence Day treat from NICE
4 July 2018 - NICE has released its final appraisal determinations for Tesaro, Pfizer and BMS cancer medicines. ...